Beta-Blocker Combination Therapy With Beta-Arrestin Pathway Modulation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a large variation among patients in responsiveness to conventional β-blockers used for treating cardiac diseases, despite their effectiveness in decreasing morbidity and mortality, as they primarily inhibit G protein-dependent signaling without activating cardioprotective beta-arrestin pathways.

Innovation Solution

Administering a therapeutically effective amount of compound 6 (Cmpd 6) and a beta-arrestin-biased β-blocker to enhance the effectiveness of β-blockers by stimulating beta-arrestin-mediated signaling pathways, thereby augmenting the therapeutic response.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional β-blockers are used to treat cardiac diseases, then morbidity and mortality decrease, but patient responsiveness varies widely due to inhibition of G protein-dependent signaling without activation of cardioprotective beta-arrestin pathways

Engineering Contradiction:

Improvetherapeutic effectivenessVSAvoidpatient responsiveness variation

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent changes the pharmacological parameter of β-blocker action by introducing compound 6, which shifts the signaling pathway from G protein-dependent to beta-arrestin-mediated cardioprotective pathways. This parameter change transforms carvedilol from a conventional beta-blocker with variable patient responsiveness into a beta-arrestin-biased agent with more consistent therapeutic effectiveness across patients.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent creates a composite pharmacological approach by combining compound 6 (a positive allosteric modulator) with beta-arrestin-biased β-blockers. This composite strategy enhances beta-arrestin-mediated signaling while maintaining beta-blocking activity, thereby improving reliability and reducing patient responsiveness variation through a multi-component therapeutic mechanism.

Inventive Principle:

Principle #40Composite materials

2Reliability

If beta-arrestin-biased β-blockers are administered to enhance cardioprotective signaling, then therapeutic effectiveness is improved, but treatment complexity increases due to combination therapy requirements

Engineering Contradiction:

Improvetherapeutic effectivenessVSAvoidtreatment regimen complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent merges the functions of compound 6 (positive allosteric modulator of beta-arrestin pathways) and beta-arrestin-biased β-blockers into a single combination therapy regimen. This merging consolidates two therapeutic mechanisms into one coordinated treatment approach, enhancing cardioprotective signaling while managing treatment complexity through integrated administration protocols.

Inventive Principle:

Principle #5Merging (Combining)

Data Source

PatentUS20260069555A1Compositions and Methods for Modulating the Effect of Beta-Blocker Activity in a Subject

Publication Date: 2026.03.12 DUKE UNIV

AI summary

The present disclosure provides compositions that provide positive allosteric modulator compounds of the beta-adrenergic receptor in combination with a beta-arrestin-biased beta-blocker, such as carvedilol, for the treatment of cardiovascular diseases and disorders, such as hypertension and heart failure, wherein the effectiveness of the beta-blocker is enhanced by positively augmenting carvedilol-stimulated cellular responses.